

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA**

**Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, stakeholders identified the following potential equality issues and requested that NICE:

- Consider that moderate and severe haemophilia B is rare in women and that the clinical trial did not include women
- Consider that AAV vectors can lead to liver toxicity and consideration should be given on use in people with cirrhosis or extensive fibrosis
- Ensure recommendations do not discriminate against people with HIV or historical hepatitis B or C
- Consider that dosing of etranacogene dezaparvovec is based on weight and that there is some suggestion that high doses of AAV vectors may be associated with higher risks.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Based on the marketing authorisation received the committee will need to ensure that the guidance does not discriminate based on gender, weight or existing chronic conditions (such as HIV, hepatitis B or C, or other liver disease).

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** ...Linda Landells  
**Date:** 28 October 2022